Navigation Links
Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
Date:10/22/2008

V3100

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer. An estimated 186,320 new cases are expected to be diagnosed in 2008, and approximately 28,660 men are expected to die this year from the disease. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Overexpression of the androgen receptor is believed to contribute to the progression of castration-resistant prostate cancer. MDV3100 is a novel small- molecule androgen receptor antagonist that inhibits androgen receptor function by blocking nuclear translocation of the androgen receptor and DNA binding.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial. In September 2008, Medivation entered into a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding future clini
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
2. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
3. Medivation Announces Participation in Upcoming Conferences
4. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
5. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
6. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
7. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
8. Medivation Announces Senior Management Promotions
9. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
10. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
11. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Mapp Biopharmaceutical,s valiant effort ... therapeutic to fight the Ebola outbreak will make ... the production of pharmaceuticals can be, according to ... that while some may be taken aback by ... with industry knowledge are well aware of the ...
(Date:10/20/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... orders to $5.8 million and provides a good start to Q4.  ... North America and one in the Middle ... at record levels," said Peter Bruijns , President & CEO. ... of Q3 than they have been for any complete year since ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
(Date:10/20/2014)... Local veterinary surgeon, Dr. Tim McCarthy is ... donor stem cells for dogs with osteoarthritis. Dr. McCarthy ... performed clinical stem cell therapy for 7 years. The ... a single injection of donor stem cells into one ... and inflammation in the treated joints. , Candidates ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... Sigma Life Science, the innovative biological ... SIAL ), announced that its SAGE Labs initiative ... Parkinson,s disease in collaboration with The Michael J. Fox ... SAGEspeed™ model creation process, these off-the-shelf rat models represent ...
... size, antennaswhether in a cell phone or on ... and bandwidth when their size is reduced below ... toward producing antennas by screen-printing, inkjet printing, and ... dipoles and loops," explained Jennifer T. Bernhard, a ...
... 16, 2011 Reportlinker.com announces that a new ... Global Growth Factors ( ... http://www.reportlinker.com/p0397766/Global-Growth-Factors--Blood-And-Tissue--Industry.html This report ... And Tissue) in US$ Million by the following ...
Cached Biology Technology:Sigma® Life Science Launches Suite of Knockout Rats to Model Parkinson's Disease 2Sigma® Life Science Launches Suite of Knockout Rats to Model Parkinson's Disease 33-D printing method advances electrically small antenna design 2Global Growth Factors ( Blood And Tissue ) Industry 2Global Growth Factors ( Blood And Tissue ) Industry 3Global Growth Factors ( Blood And Tissue ) Industry 4Global Growth Factors ( Blood And Tissue ) Industry 5Global Growth Factors ( Blood And Tissue ) Industry 6Global Growth Factors ( Blood And Tissue ) Industry 7Global Growth Factors ( Blood And Tissue ) Industry 8Global Growth Factors ( Blood And Tissue ) Industry 9Global Growth Factors ( Blood And Tissue ) Industry 10Global Growth Factors ( Blood And Tissue ) Industry 11Global Growth Factors ( Blood And Tissue ) Industry 12Global Growth Factors ( Blood And Tissue ) Industry 13Global Growth Factors ( Blood And Tissue ) Industry 14Global Growth Factors ( Blood And Tissue ) Industry 15Global Growth Factors ( Blood And Tissue ) Industry 16
(Date:10/14/2014)... – High doses of fish oil supplements, rich in omega-3 ... of irregular heartbeat in which the heart can beat as ... AFFORD trial led by the Montreal Heart Institute were published ... on October 7th. , For the trial, 337 patients ... assigned to 4 grams of fish oil a day or ...
(Date:10/14/2014)... This week, an international team of researchers, led by ... in the journal Nature Genetics a brief ... 360 varieties of the tomato plant. , The C.M. ... an important role in this study by providing seed ... , This study, which builds on the first tomato ...
(Date:10/14/2014)... – Researchers from Stanford University School of Medicine have ... cells and the activation of muscle stem cells. Cells ... energy during times of nutrient deprivation. The scientists report ... protective mechanism is operational it also seems to assist ... that when stem cells emerge from a quiescent state ...
Breaking Biology News(10 mins):Autophagy helps fast track stem cell activation 2
... comforting thought unless the living thing in question is a ... developing drug resistance, outwitting immune systems, and evading cellular controls. ... perturbations such as mutations that affect the function of vital ... perform old tasks. Somehow the bad guys find ...
... The delicate lady bug in your garden could be frighteningly ... in the air, a new study concludes. The study adds ... during the late Paleozoic period because they had a much ... , The study, "No giants today: tracheal oxygen supply to ...
... new approach to treating severe nerve pain ?by aiming drugs ... University of Utah scientists who study the venoms of deadly, ... way to treat a chronic and debilitating form of pain ... J. Michael McIntosh, a University of Utah research professor of ...
Cached Biology News:Evolution and the workaround 2Giant insects might reign if only there was more oxygen in the air 2Giant insects might reign if only there was more oxygen in the air 3A new target for painkillers 2A new target for painkillers 3A new target for painkillers 4
... These 1.5L PYREX trypsinizing ... homogenous tissue samples into cell ... proteins. Heavy beaded neck accepts ... enhance vigorous agitation. • Height ...
... of purified RNA samples., , This product ... aqueous RNA samples that have been pre-purified ... silica, oligo dT etc or other kits. ... necessary components for the stabilization of nanogram ...
Plasmid expressing the LacZ reporter gene....
Puromycin resistance gene (pac), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Biology Products: